Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Operating Income (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Operating Income data on record, last reported at -$4.6 million in Q4 2025.

  • For Q4 2025, Operating Income rose 81.15% year-over-year to -$4.6 million; the TTM value through Dec 2025 reached -$22.1 million, up 74.73%, while the annual FY2025 figure was -$22.1 million, 74.73% up from the prior year.
  • Operating Income reached -$4.6 million in Q4 2025 per MIRM's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Operating Income topped out at $2.6 million in Q3 2025 and bottomed at -$47.6 million in Q1 2021.
  • Average Operating Income over 5 years is -$26.2 million, with a median of -$26.8 million recorded in 2023.
  • Peak YoY movement for Operating Income: tumbled 116.11% in 2021, then soared 120.52% in 2025.
  • A 5-year view of Operating Income shows it stood at -$45.6 million in 2021, then rose by 25.04% to -$34.2 million in 2022, then increased by 4.61% to -$32.6 million in 2023, then increased by 25.67% to -$24.2 million in 2024, then soared by 81.15% to -$4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$4.6 million in Q4 2025, $2.6 million in Q3 2025, and -$5.0 million in Q2 2025.